IBRX ImmunityBio NASDAQ pre-market up on Q4 beat 25 Feb 2026: ANKTIVA outlook

IBRX stock is trading pre-market at $11.55 on 25 Feb 2026 after ImmunityBio reported a Q4 revenue and EPS beat. The company posted $38.29 million in Q4 revenue and an adjusted loss per share of $0.06, beating consensus by $0.02. Investors are focused on ANKTIVA commercial traction and near-term regulatory milestones ahead of the March 2, 2026 earnings call. This earnings spotlight reviews the numbers, valuation, analyst views, and what drives price action in the United States NASDAQ session.

IBRX stock: Q4 earnings snapshot

ImmunityBio reported Q4 revenue of $38.29 million, up sharply year over year and above the Zacks consensus. The company posted an adjusted EPS loss of $0.06 versus an expected -$0.08, a positive surprise that helped lift shares in pre-market trading.

Trading moved hard on the print with a session high of $12.27 and volume spiking to 82,287,047 shares versus an average of 30,229,986. Management commentary on the March 2 earnings call will be the key near-term catalyst for IBRX stock.

Commercial traction and ANKTIVA drivers

ANKTIVA drove the revenue surge: ImmunityBio reported $113.2 million net product revenue for full-year 2025, roughly 700.00% year‑over‑year growth. New distribution deals in Europe and partnerships in Saudi Arabia expand commercial reach to multiple jurisdictions and increase addressable market.

Pipeline updates also matter. Ongoing registrational trials for BCG‑naïve NMIBC and 2L+ NSCLC readouts, plus planned regulatory filings, link clinical progress to commercial scaling and IBRX stock performance.

IBRX stock valuation and financial metrics

Valuation remains stretched versus current fundamentals. Market cap is $11.38 billion while price to sales and other ratios are elevated—price-to-sales TTM is about 99.22 and P/E is negative at approximately -28.17. The company carries a large share base of 984,965,000 shares outstanding.

Cash runway appears reasonable with company-reported $242.80 million in cash and equivalents at year end, and a current ratio of 5.10, but losses persist. Investors should weigh high revenue growth against negative net income and lofty multiples when assessing IBRX stock.

Analyst consensus and Meyka AI grade

Sell‑side coverage skews positive: six Buy ratings and one Sell produce an average price target near $12.60 and a range that includes a high of $23.00 from D. Boral Capital. That consensus implies modest upside from today’s price.

Meyka AI rates IBRX with a score out of 100: 74.30 / B+ — BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are informational only and are not financial advice.

Technical read and trading risks for IBRX stock

Technicals point to a strong short‑term trend but elevated risk. RSI is 82.90 (overbought) and ADX is 53.66 indicating a strong trend. The 50‑day average is $4.35 and the 200‑day average is $2.98, showing the recent rally is extreme versus longer‑term trend.

Key risks include execution on global launches, margin expansion, continued trial success, and the company’s unprofitable status. High volume and retail interest can amplify volatility in IBRX stock.

Earnings calendar, milestones and catalysts

ImmunityBio’s next formal earnings announcement is set for March 2, 2026, and the post‑earnings call will be watched for updated guidance and commercial metrics. Upcoming regulatory filings and FDA discussions around ANKTIVA and recombinant BCG are near‑term catalysts.

Catalyst cadence: trial enrollment updates, regulatory submissions, and international launches could sustain momentum if they show continued ANKTIVA uptake and safety consistency.

Final Thoughts

Meyka AI’s forecast model projects a one‑year value of $2.19 for ImmunityBio, versus the current price of $11.55, implying a model‑based downside of -81.03%. That model is one input and appears conservative relative to sell‑side targets. The analyst consensus average price target sits at $12.60, implying +9.09% upside, while a bull scenario uses a $23.00 target. Investors face a wide outcome range: strong commercial adoption of ANKTIVA could validate high multiples and support the current rally, while slower uptake, margin pressure, or clinical setbacks would likely trigger sharp declines. For pre‑market traders in the United States NASDAQ session, focus on the March 2 earnings call for updated unit sales, gross margins, and FDA timelines. Use the Meyka AI grade and model as one data point; forecasts are model‑based projections and not guarantees. For a full data view see our IBRX page on Meyka AI and the recent coverage from Nasdaq and MarketBeat source source Meyka IBRX page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.